Bayer aims for new Xarelto nod in Japan; Purdue recruits first chief commercial officer; Durata med wins FDA clearance;

> Bayer submitted its clot-fighter Xarelto for approval in Japan, to treat deep vein thrombosis and pulmonary embolism. Report

> Purdue Pharma tapped Saeed Motahari, formerly an AbbVie ($ABBV) VP of sales and marketing, to be its first chief commercial officer. Report

> Durata Therapeutics won FDA approval for its new drug to treat serious bacterial skin infections, Dalvance. Report

> The New York-based health communications group Chandler Chicco Companies, part of inVentiv Health, expanded its digital team with three new senior-level hires. Report

> Hungary's Richter agreed to buy a 51% stake in Mediplus, a Curacao-based company that promotes its products in Latin America. Report

And Finally... The use of antidepressants in England has risen faster than ever since the recession there boosted unemployment. Report

Suggested Articles

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.